Iraqi Board Clinical Pharmacy common mistakes
Iraqi Board Clinical Pharmacy · Understand the traps and how to avoid them.
Calculating a vancomycin or aminoglycoside dose from total body weight and a population average volume of distribution, then reporting a single steady-state concentration without stating the infusion timing, sampling time, or whether the level is peak or trough.
Candidates memorise Vd and clearance values as fixed numbers and treat the calculation as the endpoint. In practice the assay result is only interpretable relative to dose timing, and obese, critically ill, or renal-replacement patients have markedly altered volumes and clearance, so the unqualified number looks confident but is clinically unusable.
What to do instead
Before any calculation, write the patient's actual body weight, adjusted or ideal body weight used, creatinine clearance method (Cockcroft-Gault with the specified body weight), and dialysis status. For each level reported, state dose given, infusion duration, time of sampling relative to end of infusion, and whether it is peak or trough. Then show the interpretation step: extrapolate to steady state or AUC, compare with the target (for example AUC24/MIC 400-600 for vancomycin in serious MRSA infection), and give a specific new dose with the planned monitoring time. Practise two or three full worked cases per session rather than isolated arithmetic.
Managing acute decompensated heart failure or a hypertensive emergency by adding or titrating oral agents while omitting the immediate life-saving sequence, for example not giving intravenous loop diuretic plus oxygen and vasodilator therapy in flash pulmonary oedema, or not starting a controlled intravenous infusion in a hypertensive emergency with end-organ damage.
Exam questions are often phrased as 'what is the next best step in pharmacotherapy', and candidates default to the chronic disease algorithm they know best. Guideline-directed medical therapy for chronic HFrEF (sacubitril/valsartan, beta-blocker, MRA, SGLT2 inhibitor) is well rehearsed, so it crowds out the acute stabilisation sequence under time pressure.
What to do instead
Build a two-column template for every major cardiovascular topic: acute/emergency management versus chronic optimisation. For acute pulmonary oedema the column must include sitting position, high-flow oxygen or non-invasive ventilation, intravenous loop diuretic, nitroglycerin if systolic pressure allows, and morphine only as a considered adjunct. For hypertensive emergency, list the preferred agent and target reduction per condition (for example labetalol or nicardipine infusion with roughly 20-25% mean arterial pressure reduction in the first hour in most cases, avoiding rapid normalisation in ischaemic stroke). Rehearse the sequence aloud until it precedes the chronic list.
Choosing an antimicrobial and duration for a specific infection without naming the likely pathogen, the local resistance pattern, source control, and the de-escalation or review point, and treating a positive culture as automatically requiring antibiotics regardless of whether it represents colonisation.
Stewardship content is often studied as a list of drug-bug pairs, which rewards recall but not clinical reasoning. Candidates also conflate 'positive culture' with 'infection', and Iraqi hospital antibiograms and drug availability differ from the international guidelines they have read, so a guideline-faithful answer can be locally wrong.
What to do instead
Answer every antimicrobial question in a fixed five-part structure: syndrome and severity, most likely pathogens, empiric regimen with dose and route justified by local susceptibility and formulary availability, source control or diagnostics needed, and the planned review at 48-72 hours with explicit de-escalation criteria. Separately memorise which specimens commonly grow colonisers (sputum, wound swabs, urine in catheterised patients) and state when treatment is withheld. When a guideline is cited, add what you would do if the local antibiogram shows higher resistance.
Initiating or adjusting insulin, levothyroxine, or a corticosteroid without stating the starting dose rationale, the titration interval, and the specific monitoring parameter and timing, for example starting basal insulin without calculating units per kilogram or without specifying when to check glucose and HbA1c.
Endocrine questions look like simple drug-selection items, so candidates answer with a drug name and stop. The actual discriminator is the dosing and monitoring plan, and candidates have usually memorised drug classes rather than the arithmetic and follow-up intervals, particularly for insulin in renal impairment and steroid replacement in adrenal insufficiency.
What to do instead
For each endocrine drug class, write a one-page card containing starting dose formula, titration step size, interval between steps, monitoring test, and target range. Examples to include: basal insulin 0.1-0.2 units/kg/day in the outpatient setting with fasting glucose titration every three days; levothyroxine roughly 1.6 micrograms/kg/day in young adults but a much lower start (for example 12.5-25 micrograms) in older patients or those with ischaemic heart disease, rechecked at six to eight weeks; stress-dose hydrocortisone in adrenal crisis. Practise writing the full plan, not just the drug name.
Treating asthma and COPD as interchangeable and answering a respiratory question with a long-acting beta-agonist alone in asthma, or with an inhaled corticosteroid as the sole maintenance agent in COPD, without addressing inhaler technique, adherence, and the exacerbation action plan.
The two diseases share bronchodilators, so candidates apply one framework to both. The safety rule that asthma must not be treated with a long-acting beta-agonist without inhaled corticosteroid, and the different role of inhaled corticosteroids in COPD, are frequently blurred, and inhaler technique is rarely mentioned because it is not a drug name.
What to do instead
Maintain a side-by-side comparison table: defining feature, preferred reliever, preferred controller, role of long-acting muscarinic antagonist and long-acting beta-agonist, when to add a leukotriene receptor antagonist or biologic, and the step-up and step-down rules. Add a mandatory paragraph to every respiratory answer covering device selection, technique demonstration, adherence check, and written exacerbation plan with when to escalate. For hepatic and gastrointestinal questions, apply the same discipline to variceal bleeding prophylaxis, spontaneous bacterial peritonitis prophylaxis, and hepatic encephalopathy precipitants.
Prescribing a full standard dose of a renally cleared or hepatically metabolised psychotropic or analgesic (for example lithium, gabapentin, morphine, or a benzodiazepine) to an older adult or a patient with organ impairment, without applying a deprescribing or dose-reduction framework and without stating the monitoring plan.
Neuropsychiatric and pain items are usually taught by indication and receptor profile, so dose individualisation for age and organ function is treated as a pharmacokinetics topic that lives in another domain. Candidates also under-weight interaction risk, such as serotonin syndrome or QT prolongation, because each drug is studied alone.
What to do instead
Attach a mandatory 'dose, interaction, monitoring' triad to every psychotropic or analgesic answer. Specify the reduced starting dose and slower titration in older adults, the renal cut-off for the drug (for example avoid or reduce gabapentin and pregabalin by creatinine clearance, avoid meperidine entirely), the specific interaction to screen for, and the monitoring test with timing (lithium level and renal and thyroid function at defined intervals, electrocardiogram for QT-prolonging combinations). Rehearse one opioid conversion and one benzodiazepine taper calculation per study session.
Answering an oncology or haematology item with a regimen name only, omitting the indication-specific line of therapy, the emetogenic risk and antiemetic prophylaxis, growth factor or febrile neutropenia plan, and the pre-treatment verification of organ function and extravasation precautions.
Regimens are long and intimidating, so candidates learn acronyms and stop there. Supportive care and safety checks feel like nursing detail rather than examinable pharmacy content, yet they are exactly where the pharmacist's contribution is assessed. Cytotoxic handling, vesicant classification, and dose modification for organ dysfunction are commonly under-prepared.
What to do instead
For each major regimen you study, write five lines: indication and line of therapy, dose and schedule with the maximum cumulative dose where relevant, emetogenic classification with the matching antiemetic prophylaxis, required baseline tests and dose-modification rules for renal or hepatic impairment and myelosuppression, and administration safety points including vesicant status and extravasation management. Add a short list of immunotherapy and targeted therapy toxicities that require urgent recognition, such as immune-related colitis or pneumonitis and tumour lysis syndrome prophylaxis.
Reading a laboratory panel as isolated abnormal numbers rather than as a pattern, for example labelling a low haemoglobin as iron deficiency without checking mean corpuscular volume, ferritin, and the inflammatory context, or interpreting a raised creatinine or potassium without relating it to volume status, medications, and the trend over time.
Laboratory interpretation is often revised as reference ranges to memorise. In the exam, the discriminator is usually the pattern and the trend, plus the effect of drugs and fluid status on the result. Candidates also forget pre-analytical confounders such as haemolysis raising potassium or biotin interfering with immunoassays.
What to do instead
Practise interpreting panels as complete sets: for anaemia, always state mean corpuscular volume, reticulocyte response, ferritin with the caveat that it rises in inflammation, and the peripheral film correlate; for renal and electrolyte abnormalities, always state volume status, relevant nephrotoxic drugs, and the previous value. Build a one-page list of common false or confounded results (haemolysed samples, contamination from the infusion arm, drug-induced assay interference) and check it before finalising any interpretation answer.
Describing a medication error or adverse drug reaction without classifying it correctly, without applying an established causality or severity tool, and without a reporting pathway, for example calling any adverse event an adverse drug reaction and omitting the yellow-card or national pharmacovigilance route and the preventability assessment.
Safety and pharmacovigilance content is frequently skimmed because it seems like common sense. Candidates therefore confuse error types (prescribing, dispensing, administration, monitoring), do not know the difference between an adverse event, an adverse drug reaction, and a side effect, and cannot name the causality algorithm or the reporting authority, which is a specific and easily secured mark.
What to do instead
Learn one causality method and one severity method well enough to apply them in writing, such as the Naranjo probability scale and the Hartwig severity scale, and be able to classify an error by stage and by whether it was preventable. Memorise the national reporting route and the minimum dataset for a report, plus the high-alert medication list and the look-alike/sound-alike and concentrated-electrolyte safeguards. Practise writing a short incident report from a scenario, including the classification, causality, severity, preventability, and corrective action.
Critically appraising a study by listing its design and sample size without computing or interpreting the effect measure, confidence interval, absolute risk reduction, number needed to treat, or whether the result crosses the clinically important threshold, and confusing statistical with clinical significance.
Biostatistics is often learned as formula recall, and candidates freeze when asked to apply it. They also default to relative risk reductions quoted in abstracts because those numbers are larger and more memorable, and they rarely check whether the trial's population and endpoints match the patient in front of them.
What to do instead
Drill a fixed appraisal sequence on short abstracts: design and allocation, population versus your patient, primary endpoint and its clinical relevance, effect size with confidence interval, absolute risk reduction and number needed to treat computed from the raw event rates, and applicability including duration and co-interventions. Practise converting relative to absolute measures by hand until it is automatic, and state explicitly when a statistically significant result is too small to change practice. Add a drug-information step: identify the primary source, the level of evidence, and whether the answer would differ for a formulary decision.
Answering a law, ethics, or professional practice item with general good-practice language instead of the specific Iraqi regulatory requirement, such as the correct authority for registration, controlled-drug record-keeping and prescription validity, dispensing and substitution rules, or the mandatory reporting and consent obligations.
Candidates study clinical content far more than regulation, and much of the regulatory material is learned on the job or in Arabic-language documents that are not indexed the way textbooks are. Under exam pressure they substitute international norms or vague ethical phrasing for the specific national rule, which reads plausibly but scores nothing.
What to do instead
Build a jurisdiction-specific fact sheet and verify each line against a current official source before relying on it: which body registers medicines and licenses pharmacies, prescription retention and controlled-substance requirements, substitution and generic dispensing rules, advertising restrictions, and the professional obligations around confidentiality, consent, and error disclosure. Where you cannot confirm a detail with confidence, mark it for verification rather than guessing. Rehearse short scenario answers that name the rule, the authority, and the action the pharmacist must take.